Omvoh vs Humira for Crohn's Disease: A Comparison

Omvoh and Humira are two biologics for moderate-to-severe Crohn's disease that work through very different mechanisms. Humira is a fully human anti-TNF biologic with more than two decades of experience in IBD. Omvoh is an IL-23 p19-selective biologic approved for Crohn's in January 2025 based on the VIVID-1 trial. Patients weighing these two drugs are often choosing between an established anti-TNF and a newer IL-23 option. This guide walks through the omvoh vs humira crohn's decision.

IL-23 p19 vs Anti-TNF Mechanism

Humira (adalimumab) is a fully human monoclonal antibody that binds TNF-alpha and reduces inflammation systemically. Its broad effect covers extraintestinal manifestations of Crohn's like arthritis, psoriasis, and uveitis, but it also raises systemic infection risk. Omvoh (mirikizumab) binds the p19 subunit of interleukin-23, selectively blocking only IL-23. IL-23 is a key driver of the Th17 pathway that fuels Crohn's inflammation. The mirikizumab vs adalimumab distinction shapes both efficacy patterns and safety. Humira's broader TNF blockade produces fast systemic anti-inflammatory effects. Omvoh's narrower IL-23 target tends to produce a cleaner long-term safety profile with strong efficacy on endoscopic endpoints.

VIVID-1: Omvoh's Crohn's Evidence

VIVID-1 was the pivotal phase 3 trial for mirikizumab in Crohn's. The trial randomized biologic-naive and biologic-experienced patients with moderate-to-severe Crohn's to mirikizumab, ustekinumab (as an active comparator), or placebo. At week 12, mirikizumab showed significant improvements in clinical response, and by week 52, the trial demonstrated sustained clinical remission and endoscopic response at rates comparable to ustekinumab and superior to placebo. Two-year extension data has continued to support durable outcomes on mirikizumab, which is unusual among newer biologics because most have shorter follow-up data. No head-to-head trial has directly compared Omvoh with Humira in Crohn's. Indirect comparisons suggest generally similar clinical remission rates, with Omvoh offering potentially better long-term safety.

Onset of Action

Humira tends to produce early symptom improvement within the first few weeks of induction, with most responders showing benefit by week 8. Omvoh's onset is comparable or slightly slower, with meaningful response typically by week 12 based on VIVID-1 data. For Crohn's patients with acute symptoms who need rapid relief, Humira's fast onset is often preferred. For patients in less acute states or those prioritizing long-term safety, Omvoh's strong response through the induction window is generally acceptable.

Safety Profiles

Humira carries anti-TNF class risks of serious infections, TB and hepatitis B reactivation, and a small increase in lymphoma risk. Omvoh's safety data from the UC (LUCENT) and Crohn's (VIVID-1) programs has been favorable, with lower serious infection rates than anti-TNFs. Injection-site reactions occur with both drugs but tend to be mild. For omvoh vs humira side effects, patients with infection concerns, cancer history, or other risk factors for immunosuppression complications often find Omvoh's narrower mechanism more reassuring. Both drugs require TB and hepatitis B screening before starting, and both can be used as monotherapy.

Administration and Dosing

Humira is a subcutaneous injection throughout. Induction is 160 mg on day 1 and 80 mg on day 15, followed by 40 mg every other week, per AbbVie's prescribing information. Omvoh for Crohn's uses IV induction at weeks 0, 4, and 8 (900 mg per infusion), followed by subcutaneous maintenance of 300 mg every 4 weeks or monthly dosing options depending on response. For Crohn's patients who want all-SC administration without IV induction, Humira is simpler. For patients willing to accept three IV induction doses in exchange for a narrower immune mechanism and the extensive two-year safety data supporting Omvoh, the trade-off may favor the newer agent.

Biologic-Experienced Patients

For Crohn's patients who have already failed an anti-TNF, VIVID-1 included a biologic-experienced cohort and showed meaningful response rates on Omvoh. Real-world cohorts for Humira in biologic-experienced patients show reduced response rates when cycling within the anti-TNF class, which is why a mechanism change to IL-23 pathway blockade is often preferred. For the omvoh vs humira effectiveness decision in anti-TNF experienced patients, Omvoh typically delivers better outcomes than a second anti-TNF would. For biologic-naive patients, both drugs are reasonable first-line options with somewhat different efficacy and safety profiles.

Cost and Access

Humira faces extensive biosimilar competition. Multiple adalimumab biosimilars are designated interchangeable with Humira, including Amjevita, Cyltezo, Hyrimoz, Abrilada, Hulio, Simlandi, and Yuflyma. Many pharmacy benefit managers prefer biosimilar adalimumab over the branded drug. Omvoh has no biosimilar and is priced as a branded biologic. For Crohn's patients where insurance favors a low-cost adalimumab biosimilar, Humira (or its biosimilar) may be the most accessible option. For patients whose plans cover Omvoh and prioritize the IL-23 mechanism, manufacturer copay assistance programs can help bridge the cost gap.

Choosing With Your GI

For a Crohn's patient deciding between Omvoh and Humira, both drugs offer meaningful response in biologic-naive patients. Humira tends to win on speed of onset, biosimilar cost savings, and coverage of extraintestinal manifestations. Omvoh tends to win on long-term safety, durable two-year efficacy data, and performance in anti-TNF experienced patients. Ask your GI how response will be measured after induction, what to do if symptoms persist, and how your insurance handles adalimumab biosimilars versus branded IL-23 biologics. A log of stool frequency, urgency, abdominal pain, and any new symptoms between visits gives your care team the data to recognize early loss of response before a full flare returns.